Abstract
Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 518-521 |
| Number of pages | 4 |
| Journal | European Psychiatry |
| Volume | 27 |
| Issue number | 7 |
| DOIs | |
| State | Published - Oct 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Cognitive function
- Major depression
- One-carbon cycle
- Pharmacotherapy
- S-adenosylmethionine
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. / Levkovitz, Y.; Alpert, Jonathan E.; Brintz, C. E.; Mischoulon, D.; Papakostas, G. I.
In: European Psychiatry, Vol. 27, No. 7, 10.2012, p. 518-521.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder
AU - Levkovitz, Y.
AU - Alpert, Jonathan E.
AU - Brintz, C. E.
AU - Mischoulon, D.
AU - Papakostas, G. I.
PY - 2012/10
Y1 - 2012/10
N2 - Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.
AB - Major depressive disorder (MDD) is often accompanied by significant cognitive impairment, and there are limited interventions specific to this particular symptom. S-adenosylmethionine (SAMe), a naturally occurring molecule which serves as a major methyl-donor in human cellular metabolism, is required for the synthesis and maintenance of several neurotransmitters that have been implicated in the pathophysiology and treatment of cognitive dysfunction in MDD. Objectives: This study is a secondary analysis of a clinical trial involving the use of adjunctive SAMe for MDD. Methods: Forty-six serotonin-reuptake inhibitor (SRI) non-responders with MDD enrolled in a 6-week, double-blind, randomized trial of adjunctive oral SAMe were administered the self-rated cognitive and physical symptoms questionnaire (CPFQ), a validated measure of cognitive as well as physical symptoms of MDD, before and after treatment. Results: There was a greater improvement in the ability to recall information (P=0.04) and a trend towards statistical significance for greater improvement in word-finding (P=0.09) for patients who received adjunctive SAMe than placebo. None of the remaining five items reached statistical significance. Conclusions: These preliminary data suggest that SAMe can improve memory-related cognitive symptoms in depressed patients, and warrant replication.
KW - Cognitive function
KW - Major depression
KW - One-carbon cycle
KW - Pharmacotherapy
KW - S-adenosylmethionine
UR - http://www.scopus.com/inward/record.url?scp=84866465151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866465151&partnerID=8YFLogxK
U2 - 10.1016/j.eurpsy.2011.03.006
DO - 10.1016/j.eurpsy.2011.03.006
M3 - Article
C2 - 21665441
AN - SCOPUS:84866465151
VL - 27
SP - 518
EP - 521
JO - European Psychiatry
JF - European Psychiatry
SN - 0924-9338
IS - 7
ER -